Gene Immunotherapy for Non-Small Cell Lung Cancer
互联网
481
Historically, limited results have been observed with immunity in non-small cell lung cancer (NSCLC). In the last 5 years,
however, several immune-stimulating products have demonstrated enhancement of tumor antigen recognition through activation
of dendritic cell-involved processes. Moreover, clinical benefit has been demonstrated in subsets of patients, justifying
ongoing phase III investigation. Results of key gene immunotherapies being tested in NSCLC are reviewed. Preliminary results
in advanced NSCLC suggest evidence of well-tolerated immune activation with suggested evidence of clinical benefit with respect
to survival and response.
